Cel-Sci Corporation

CVM Healthcare Biotechnology

In the quarter to June 2026, EPS grew 65.4%, free cash flow fell 2.33% and total debt fell 39.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

1.79 0.05 +2.87%
Market cap
$30.6M
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
—
F-score
4/9
Altman Z
−1.64
Beneish M
−2.35
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(176.32%) (212.12%) (305.27%) (252.53%)
ROA
(92.16%) (97.99%) (114.90%) (108.91%)
ROIC
(145.08%) (146.58%) (147.48%) (169.59%)
Return on Tangible Assets
(202.56%) (314.90%) (719.09%) (324.19%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(4.23) (2.12) (2.05) (1.38)
Free Cash Flow
(17.16) (17.00) (16.65) (16.75)
Other line items

Show all line items

Columns are period end dates